SAN
FRANCISCO, Oct. 31, 2023 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) will announce its financial results for
the third quarter 2023 on Tuesday, November
7, 2023, after the close of U.S.-based financial markets.
Howard Robin, President and Chief
Executive Officer, will host a conference call to review the
results beginning at 5:00 p.m. Eastern
Time/2:00 p.m. Pacific
Time.
The press release and live audio-only webcast of the conference
call can be accessed through a link that is posted on the Home Page
and Investors section of the Nektar website: http://ir.nektar.com/.
The web broadcast of the conference call will be available for
replay through December 8, 2023.
To access the conference call, please pre-register at Nektar
Earnings Call Registration. All registrants will receive dial-in
information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a
robust, wholly owned R&D pipeline of investigational medicines
in immunology and oncology as well as a portfolio of approved
partnered medicines. Nektar is headquartered in San Francisco, California, with additional
manufacturing operations in Huntsville,
Alabama. Further information about the company and its drug
development programs and capabilities may be found online at
http://www.nektar.com.
Contact:
For Investors:
Vivian Wu of Nektar
Therapeutics
628-895-0661
For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-third-quarter-2023-on-tuesday-november-7-2023-after-close-of-us-based-financial-markets-301973407.html
SOURCE Nektar Therapeutics